Results 31 to 40 of about 203,196 (295)

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

open access: yes, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani   +59 more
core   +1 more source

Occurrence of chronic lymphocytic leukemia in patients with chronic myelogenous leukemia

open access: yesIndian Journal of Pathology and Microbiology, 2013
Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in the western world and constitutes about 33% of all leukemia′s. The incidence of CLL increases with age and are more common in older population.
Pritish K Bhattacharyya
doaj   +1 more source

Autoimmune Hemolytic Anemia After Relapse of Chronic Myeloid Leukemia: A Case Report

open access: yesClinical Medicine Insights: Blood Disorders, 2019
Autoimmune hemolytic anemia is one of the differential diagnoses for anemia in patients with lymphoproliferative neoplasia, such as chronic lymphocytic leukemia, who experience sudden drop in hemoglobin.
Tahseen Hamamyh, Mohamed A Yassin
doaj   +1 more source

Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature

open access: yesJournal of Medical Case Reports, 2018
Background Chronic lymphocytic leukemia and chronic myeloid leukemia are the most common types of adult leukemia. However, it is rare for the same patient to suffer from both.
Khadega A. Abuelgasim   +6 more
doaj   +1 more source

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation [PDF]

open access: yes, 2017
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for patients with acute myeloid leukemia (AML). However, post-HCT relapse and regimen-related toxicity remain significant barriers to long-term survival.
Al Mumma   +41 more
core   +1 more source

Targeting self-renewal pathways in myeloid malignancies [PDF]

open access: yes, 2013
A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core   +2 more sources

Chronic Myeloid Leukemia in 2007 [PDF]

open access: yesJournal of Managed Care Pharmacy, 2007
Chronic myeloid leukemia (CML), a hematopoietic stem cell cancer representing 15-20% of adult leukemias, is discussed. Epidemiology, staging biology, and monitoring techniques are reviewed.CML is a myeloproliferative disorder that affects all lineages of hematopoiesis.
openaire   +3 more sources

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

open access: yes, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T.   +5 more
core   +1 more source

Chronic lymphocytic leukemia developing in a case of chronic myelogenous leukemia - accelerated phase: A rare case with review of the literature

open access: yesIndian Journal of Pathology and Microbiology, 2013
Chronic myelogenous leukemia (CML) and chronic lymphocytic leukemia (CLL) are two different and common hematological neoplasms. Their coexistence is rare, especially CLL developing in a patient of CML. Till date, only a few cases are reported and all had
Narender Kumar   +3 more
doaj   +1 more source

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

open access: yes, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves   +37 more
core   +1 more source

Home - About - Disclaimer - Privacy